Patents by Inventor Pieter Coussement
Pieter Coussement has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240191270Abstract: The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of metabolically engineered cells and use of said cell in a cultivation, preferably a fermentation. The present invention describes a cell for the production of a compound. The cell comprises a pathway for the production of the compound, which can be a disaccharide, oligosaccharide and/or a Neu(n)Ac-containing bioproduct, wherein (n) is 4, 5, 7, 8 or 9 or a combination thereof. The cell is metabolically engineered for enhanced synthesis of acetyl-Coenzyme A. The invention also resides in a method of producing such compound by cultivation, preferably a fermentation, with such a cell.Type: ApplicationFiled: April 15, 2022Publication date: June 13, 2024Inventors: Joeri Beauprez, Pieter Coussement, Thomas Decoene
-
Publication number: 20240076704Abstract: Described is a method of producing bioproducts by fermentation with a genetically modified cell, as well as to the genetically modified cell used in the method. The cell is genetically modified to produce a bioproduct and is further genetically modified by reducing the expression of at least one endogenous membrane protein encoding gene and/or mutating the expression of the endogenous membrane protein.Type: ApplicationFiled: October 14, 2020Publication date: March 7, 2024Inventors: Joeri Beauprez, Pieter Coussement, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren, Sofie Aesaert, Thomas Decoene
-
Publication number: 20230416796Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. Described is the use of a new type of galactosyltransferases for the production of a galactosylated di- or oligosaccharide. The disclosure also describes methods for the production of a galactosylated di- or oligosaccharide as well as the purification of the di- or oligosaccharide. Furthermore, the disclosure is in the field of cultivation or fermentation of metabolically engineered cells. The disclosure provides a cell metabolically engineered for production of a galactosylated di- or oligosaccharide.Type: ApplicationFiled: February 10, 2023Publication date: December 28, 2023Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
-
Publication number: 20230399670Abstract: This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of fermentation of metabolically engineered microorganisms. This disclosure describes engineered micro-organisms able to synthesize sialylated compounds via an intracellular biosynthesis route. These micro-organisms can dephosphorylate N-acetylglucosamine-6-phosphate to N-acetyl glucosamine and convert the N-acetylglucosamine to N-acetylmannosamine. These micro-organisms also have the ability to convert N-acetylmannosamine to N-acetyl-neuraminate.Type: ApplicationFiled: November 23, 2022Publication date: December 14, 2023Applicant: Inbiose N.V.Inventors: Joeri Beauprez, Pieter Coussement, Dries Van Herpe, Gert Peters, Annelies Vercauteren
-
Publication number: 20230313253Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a method for the production of a di- or oligosaccharide with an N-acetylglucosamine at the reducing end by a cell as well as the purification of the di- or oligosaccharide from the cultivation. Furthermore, the disclosure provides a cell metabolically engineered for production of a di- or oligosaccharide with an N-acetylglucosamine at the reducing end.Type: ApplicationFiled: August 10, 2021Publication date: October 5, 2023Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
-
Publication number: 20230313252Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of metabolically engineered cells and use of the cells in a cultivation or fermentation. The disclosure describes a metabolically engineered cell and a method by cultivation or fermentation with the cell for production of a sialylated di- and/or oligosaccharide. The metabolically engineered cell comprises a pathway for production of the sialylated di- and/or oligosaccharide and is modified for expression and/or overexpression of multiple coding DNA sequences encoding one or more isoproteins that catalyze the same chemical reaction. Furthermore, the disclosure provides for purification of the sialylated di- and/or oligosaccharide from the cultivation.Type: ApplicationFiled: August 10, 2021Publication date: October 5, 2023Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle
-
Publication number: 20230287470Abstract: This disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. This disclosure provides a method for the production of a mixture of at least two different oligosaccharides by a cell as well as the purification of at least one of the oligosaccharides from the cultivation. In addition, this disclosure provides a method for the production of a mixture of at least two different oligosaccharides by a metabolically engineered cell as well as the purification of at least one of the oligosaccharides from the cultivation.Type: ApplicationFiled: August 10, 2021Publication date: September 14, 2023Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
-
Publication number: 20230279403Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a cell metabolically engineered for production of an alpha-1,3 glycosylated form of fucose-alpha1,2-galactose-R (Fuc-a1,2-Gal-R). Furthermore, the disclosure provides a method for the production of an alpha-1,3 glycosylated form of Fuc-a1,2-Gal-R by a cell as well as the purification of the alpha-1,3 glycosylated form Fuc-a1,2-Gal-R from the cultivation.Type: ApplicationFiled: August 10, 2021Publication date: September 7, 2023Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
-
Publication number: 20230265399Abstract: The disclosure is in the technical field of synthetic biology and metabolic engineering. More particularly, the disclosure is in the technical field of cultivation or fermentation of metabolically engineered cells. The disclosure describes a cell metabolically engineered for production of a mixture of at least four different neutral non-fucosylated oligosaccharides. Furthermore, the disclosure provides a method for the production of a mixture of at least four different neutral non-fucosylated oligosaccharides by a cell as well as the purification of at least one of the oligosaccharides from the cultivation.Type: ApplicationFiled: August 10, 2021Publication date: August 24, 2023Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle, Annelies Vercauteren
-
Publication number: 20230212628Abstract: The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered host cells. The present invention describes a method of making sialylated oligosaccharide by fermentation with a genetically modified cell, as well as to the genetically modified cell used in the method. The genetically modified cell comprises at least one nucleic acid sequence coding for an enzyme involved in sialylated oligosaccharide synthesis and at least one nucleic acid expressing a membrane protein.Type: ApplicationFiled: December 18, 2020Publication date: July 6, 2023Inventors: Joeri Beauprez, Pieter Coussement, Thomas Decoene, Annelies Vercauteren
-
Publication number: 20230174991Abstract: This disclosure relates to the technical field of synthetic biology and metabolic engineering. More particularly, this disclosure relates to the technical field of fermentation of metabolically engineered microorganisms. This disclosure describes engineered micro-organisms that produce oligosaccharides that are free of KDO-lactose impurities and/or KDO-oligosaccharide impurities.Type: ApplicationFiled: February 12, 2021Publication date: June 8, 2023Inventors: Joeri Beauprez, Pieter Coussement, Gart Peters
-
Patent number: 11535878Abstract: The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered microorganisms. The present invention describes engineered microorganisms able to synthesize sialylated compounds via an intracellular biosynthesis route. These microorganisms can dephosphorylate N-acetylglucosamine-6-phosphate to N-acetylglucosamine and convert the N-acetylglucosamine to N-acetylmannosamine. These microorganisms also have the ability to convert N-acetylmannosamine to N-acetyl-neuraminate.Type: GrantFiled: December 26, 2017Date of Patent: December 27, 2022Assignee: INBIOSE N.V.Inventors: Joeri Beauprez, Pieter Coussement, Dries Van Herpe, Gert Peters, Annelies Vercauteren
-
Publication number: 20220396817Abstract: The present disclosure is in the technical field of synthetic biology and metabolic engineering. The disclosure provides engineered viable bacteria. In particular, the disclosure provides viable bacteria with reduced cell wall biosynthesis additionally modified for production of glycosylated product. The disclosure further provides methods of generating viable bacteria and uses thereof. Furthermore, the disclosure in the technical field of fermentation of metabolically engineered microorganisms producing glycosylated product.Type: ApplicationFiled: February 12, 2021Publication date: December 15, 2022Inventors: Sofie Aesaert, Joeri Beauprez, Pieter Coussement, Thomas Decoene, Nausicaä Lannoo, Gert Peters, Kristof Vandewalle
-
Publication number: 20220298530Abstract: The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention relates to a method to determine the expression stability of a heterologous gene at a chromosomal location in a cell undergoing burden and to produce mutated cells or organisms transformed with a heterologous gene at a chromosomal location, wherein the expression of said heterologous gene is not influenced by a burden or wherein the expression of said heterologous gene is reduced by a burden. The present invention describes methods to locate interesting chromosomal knock-in locations in a cell. Such engineered cells and organisms are applied for the production of bioproducts, such as but not limited to carbohydrates, lipids, proteins, organic acids, amino acids, alcohols, antibiotics and peptides. Preferably, the invention is applied in the technical field of fermentation of metabolically engineered microorganisms.Type: ApplicationFiled: June 4, 2020Publication date: September 22, 2022Applicant: INBIOSE N.V.Inventors: Joeri Beauprez, Pieter Coussement, Sofie De Maeseneire, Anke Goormans, Gert Peters, Nico Snoeck, Dries Van Herpe
-
Publication number: 20210355520Abstract: A method or producing amino sugar (containing) products using metabolically engineered microorganisms is disclosed, wherein the conversion of UDP-N-acetylglucosamine to cell envelope precursors and molecules is reduced by altering the activity of enzymes involved in the synthesis of cell envelope precursors and molecules.Type: ApplicationFiled: September 20, 2019Publication date: November 18, 2021Inventors: Jo Maertens, David Bauwens, Wouter Van Bellegem, Pieter Coussement, Dries Duchi, Marjan De Mey
-
Publication number: 20190338328Abstract: The present invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the present invention is in the technical field of fermentation of metabolically engineered microorganisms. The present invention describes engineered microorganisms able to synthesize sialylated compounds via an intracellular biosynthesis route. These microorganisms can dephosphorylate N-acetylglucosamine-6-phosphate to N-acetylglucosamine and convert the N-acetylglucosamine to N-acetylmannosamine. These microorganisms also have the ability to convert N-acetylmannosamine to N-acetyl-neuraminate.Type: ApplicationFiled: December 26, 2017Publication date: November 7, 2019Applicant: INBIOSE N.V.Inventors: Joeri Beauprez, Pieter Coussement, Dries Van Herpe, Gert Peters, Annelies Vercauteren